[52] R&D spending reached a record high of $317 million in 2013 up 83% from the previous year. In the past three months, Alexion Pharmaceuticals insiders have sold more of their company's stock than they have bought. Since the targeted user base is small for such drugs, clinical drugs tend to be quicker[vague] and cheaper than those for mass market drugs. But that’s not new. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. [15] In March 2017, Alexion named Ludwig N. Hantson as its new CEO. Yahoo Finance Video. [34] It costs £340,200 per year for treatment in the UK[38][39] and $500,000 a year in Canada. The boy's medicine cost 9,000 euros every two weeks. Alexion Pharmaceuticals is headquartered at 121 SEAPORT BOULEVARD, BOSTON MA, 02210. Despite growing its EBITDA per share by nearly 100% since 2018, the company’s stock … Alexion Pharmaceuticals updated its FY 2020 QQQ 318.04. Alexion Pharmaceuticals had a return on equity of 23.16% and a net margin of 16.32%. To see all exchange delays and terms of use please see disclaimer. View which stocks have been most impacted by COVID-19. It employs around 2,400 people worldwide. Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter. BioCryst's antiviral drug RAPIVAB was approved by FDA in December 2014. Alexion Pharmaceuticals' management team includes the following people: Buy This Ticker Now: Projected To Jump 1,530%, With experts projecting gains as high as 1,530% by the end of this year… Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. View all of ALXN's competitors. Receive a free world-class investing education from MarketBeat. [25], In April 2018, Alexion announced the acquisition of Wilson Therapeutics for $855 million. Shares of ALXN can be purchased through any online brokerage account. [25] "The success of specialty drugs for rare diseases comes at a time when the traditional drug business of selling medicines to the masses is in decline...Specialty drugs have gotten more expensive than anyone imagined. The institutional investor owned 3,214 shares of the biopharmaceutical company’s stock after acquiring an additional 714 shares during the period. Wall Street analysts have given Alexion Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. [11] In 2000, Alexion moved its headquarters from New Haven to Cheshire, Connecticut. Elliott argues that Alexion management's actions, including the o.m. Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), AbbVie (ABBV), Tesla (TSLA), Broadcom (AVGO), The Walt Disney (DIS) and Visa (V). The drug blocks part of the immune system at a time when conventional wisdom says that the immune system must be fully charged to whip the virus. The trials failed. View Alexion Pharmaceuticals' earnings history. Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). The official website for Alexion Pharmaceuticals is www.alexion.com. View Top Holdings and Key Holding Information for iShares Nasdaq Biotechnology In (IBB). [30], In May 2020, Alexion announced an agreement to acquire Portola Pharmaceuticals for $18 per share using cash. Alexion is well on the way to developing a second very high price and high margined drug. Learn more. [25], Pharmaceutical Research and Manufacturers of America, https://ir.alexion.com/news-releases/news-release-details/alexion-reports-fourth-quarter-and-full-year-2019-results#:~:text=BOSTON%20%2D%2D(BUSINESS%20WIRE)%2D%2D,percent%20increase%20compared%20to%202018, "Alexion Pharmaceuticals 2017 Annual Report Form (10-K)", "Alexion Submits Application for Soliris", "Alexion Pharmaceuticals on the Forbes World's Most Innovative Companies List", "Everything you need to know about the $8.4B acquisition of Synageva", "Photos of Alexion Pharmaceuticals World HQ Dedication", "Alexion Exits New Haven For Boston, Agrees To Repay Millions In State Aid", "More Support for Long-Term Plavix to Improve Stent Safety", "How A $440,000 Drug Is Turning Alexion Into Biotech's New Innovation Powerhouse", "Alexion to Buy Synageva for $8.4 Billion", "Alexion treating Europe's E coli victims", "Alexion Pharmaceuticals, Inc. to Join the NASDAQ-100 Index Beginning April 4, 2011", "Teva wins controversial PhRMA bid despite protests from branded rivals - FiercePharma", "Alexion's Board of Directors Announces New Leadership Appointments | Alexion Pharmaceuticals, Inc", "Alexion Pharma names former Baxalta chief Ludwig Hantson CEO", "Alexion closing RI manufacturing facility, 250 losing jobs", https://ir.alexion.com/news-releases/news-release-details/astrazeneca-acquire-alexion-accelerating-companys-strategic-and, "AstraZeneca makes $39bn swoop for rare diseases firm Alexion", "Alexion Buys Calif. Firm;Proliferon acquired in $41 million deal", "Securities and Exchange Commission Alexion 8-K 2000 Report", "Alexion to Pay as Much as $1.08 Billion to Buy Enobia Pharma", "How Genzyme became a source of biotech executives", "Alexion Puts Its Soaring Stock Price to Good Use", "Biotech M&A rolls on as Alexion snaps up Wilson for $855 million", "Alexion to Acquire Wilson Therapeutics for $855M - GEN", "Alexion to Acquire Syntimmune for Up to $1.2B, Expanding Rare Disease Pipeline", "Alexion to buy biotech firm Syntimmune for up to $1.2 billion", https://www.biospace.com/article/alexion-buys-achillion-in-930-million-cash-deal/?s=79, "Elliott Advisors (UK) Limited sent the following letter to the Board of Alexion today", "Alexion Pharmaceuticals, Inc. (ALXN) Ownership Summary", "Soliris® (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS)", "Doctors must tell patients of errors, under new Varadkar law", "High cost of treatment for rare blood disorder needs to be clarified, says NICE in draft guidance", "Viktor (7) moet elke twee weken infuus krijgen van 9.000 euro", "Pr-bureau van farmabedrijf adviseerde ook ouders Viktor", "Farmabedrijf Alexion heeft Viktor "gebruikt, "Farmabaas fluit Alexion terug in zaak-Viktor", "Detiège: "Dit is chantage van het farmabedrijf, "Medicijn Viktor vanaf juli terugbetaald", "Contract van Onkelinx met farmareus opent doos van Pandora", "Alexion Pharmaceuticals Stock Jumps on FDA Approval of Soliris", "Alexion Pharma (ALXN) Receives New Japanese Patent for Soliris", "Biotech blastoff: Synageva up 112% on $8B Alexion deal", "Alexion Pharmaceuticals, Inc. - Annual Report", Pharmaceutical companies of the United States, https://en.wikipedia.org/w/index.php?title=Alexion_Pharmaceuticals&oldid=1010640855, Health care companies based in Massachusetts, Pharmaceutical companies established in 1992, Short description is different from Wikidata, All Wikipedia articles needing clarification, Wikipedia articles needing clarification from June 2018, Official website different in Wikidata and Wikipedia, Creative Commons Attribution-ShareAlike License. This move was aimed to diversify Alexion's hematology, neurology, and critical care commercial portfolio with Portola's Factor Xa inhibitor reversal agent. Because it offers a treatment for several conditions with limited therapeutic options, demand for Solaris is incredibly high. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. Since then, ALXN shares have increased by 81.0% and is now trading at $151.59. Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021. But if it had worked for arthritis, Alexion would likely have had to charge a much lower price for this use, as it would have to compete against drugs that cost a mere $20,000." It is the producer of Solaris, a treatment that’s currently indicated for patients with four rare conditions who previously had few or no treatment options. Alexion Pharmaceuticals had a net margin of 16.32% and a trailing twelve-month return on equity of 23.16%. ), Alexion Pharmaceuticals has received 770 “underperform” votes. Alexion Pharmaceuticals employs 3,082 workers across the globe. (Add your “underperform” vote.). Alexion Pharmaceuticals (ALXN) stock rose yesterday based on a rare and counterintuitive drug called Soliris to treat coronavirus. stock was originally listed at a price of $3.13 in Dec 31, 1997. [9][10] Bell served as the company's CEO until 2015. Alexion Pharmaceuticals has received 1,250 “outperform” votes. S&P 500 3,939.34. Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. 318%. It has also been approved in Japan, Korea and China. At the same time, Pharma opened a court case against Alexion Pharma Belgium. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). If you had invested in Alexion Pharmaceuticals stock at $3.13, your return over the last 23 years would have been 4,788%, for an annualized return of 18.42%. ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report? The company’s stock price has collected -1.30% of loss in the last five trading sessions. [12], In April 2011, Alexion was added to the NASDAQ-100, a group composed of the 100 largest non-financial stocks traded on the NASDAQ; with a market value of US$8.5 billion it replaced Genzyme Corporation. Vote “Underperform” if you believe ALXN will underperform the S&P 500 over the long term. Learn everything you need to know about successful options trading with this three-part video course. Alexion ($23 billion, -3% YTD) is a pharma company best known for Soliris, a drug used to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria - two rare disorders. [13], In April 2015, Bell was replaced as CEO by David Hallal. The FDA's decision to grant approval received a positive response from the medical community with the director of Pediatric Nephrology at Atlanta's Children's hospital calling it "the most important advance that has been made for patients and families with this disease". [6] In February 2016, the company held the dedication ceremony for its new headquarters in New Haven, Connecticut, not far from the company's starting point in the same city. Analysts expect Alexion Pharmaceuticals to post earnings of $2.25 per share for the quarter. Looking for new stock ideas? MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. However, on June 12, Alexion received a court gag order against Pharma, preventing it from communicating its investigation. Learn more. Returns as of 3/11/2021. [7], In September 2017, Alexion announced it would be moving its headquarters to Boston, Massachusetts, in mid-2018.[8]. Business data for Alexion Pharmaceuticals: This page was last edited on 6 March 2021, at 14:58. Operating Margin for any stock indicates how profitable investing would be, and Alexion Pharmaceuticals Inc. [ALXN] shares currently have an operating margin of +42.45 and a Gross Margin at +85.79. 02:51PM : 53% of executives say their companies plan to increase M&A in 2021: PwC. J&J (JNJ) Q4 Earnings & Sales Beat, 2021 Guidance Upbeat. Q3 2020. Alexion Pharmaceuticals, Inc.'s score of Press Release reported on 01/25/21 that Alexion to Report Fourth Quarter and Full Year 2020 Results on Thursday, February 4, 2021 IBD Newsletters Get exclusive IBD analysis and action news daily. Valuing Alexion Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alexion Pharmaceuticals's overall performance. [41] On May 4, 2013, De Standaard reported that a press relations (PR) agency working for Alexion had helped the boy's parents communicate their story to the press. MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Due to the niche nature of its market and the high cost of Soliris, the company has enjoyed a high profit margin. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Alexion Pharmaceuticals stock hasn’t moved much this year. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. Alexion Pharmaceuticals's P/E ratio. In October 2015, Alexion's second drug, Strensiq (asfotase alfa), was approved by the US FDA. Earnings for Alexion Pharmaceuticals are expected to grow by 5.30% in the coming year, from $11.14 to $11.73 per share. Over the next 52 weeks, Alexion Pharmaceuticals Inc has on average historically risen by 51.6 % based on the past 24 years of stock performance. Investors could be forgiven for running out of patience with Alexion Pharmaceuticals (NASDAQ: ALXN). NASDAQ:ALXN opened at $154.86 on Wednesday. There is an ethical question as to the pricing of the drug and the ethics of the drug manufacturer. Get daily stock ideas top-performing Wall Street analysts. Vote “Outperform” if you believe ALXN will outperform the S&P 500 over the long term. By May 28th, Americans could be faced with a difficult choice: Accept a "Great Reset" and risk losing the American way of life... or stand up and fight back to save what's left of the American dream. [45] By May 7, 2013 an agreement had been reached to reimburse the medicine. [11] It also represented a valuation of about ten times projected peak sales, double what is typical for the biotech industry. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Alexion Pharmaceuticals against related stocks people have also bought. This suggests a possible upside of 2.7% from the stock's current price. The biopharmaceutical company earned $1.59 billion during the quarter, compared to analyst estimates of $1.51 billion. [38][39][40] and US$409,500 a year in the United States (2010). [37], By 2010 Soliris was considered to be the most expensive drug in the world. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. There are currently 16 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. Find the latest Alexion Pharmaceuticals, Inc. (ALXN) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. © [43][44] Several politicians stated that the company was attempting to 'blackmail' the government, charges which Alexion denied. During the same quarter in the previous year, the firm earned $2.71 EPS. Shares of Alexion Pharmaceuticals Inc. ALXN, +2.11% slid 0.51% to $151.97 Monday, on what proved to be an all-around great trading session for … View analyst ratings for Alexion Pharmaceuticals or view top-rated stocks. Free forex prices, toplists, indices and lots more. Alexion Pharmaceuticals was founded in 1992 at Science Park in New Haven, Connecticut by Steven Squinto and Leonard Bell. Q2 2020. Financial performance. View our earnings forecast for Alexion Pharmaceuticals. View insider buying and selling activity for Alexion Pharmaceuticals or view top insider-selling stocks. View analysts' price targets for Alexion Pharmaceuticals or view top-rated stocks among Wall Street analysts. Real time Alexion Pharmaceuticals (ALXN) stock price quote, stock graph, news & analysis. [11] In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). Kanuma, which Alexion acquired in its acquisition of Synageva, was approved in 2015 to treat lysosomal acid lipase deficiency, a fatal genetic disorder that cause fatty material to build up in blood vessel walls, the liver, and other tissues. Valuing Alexion Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alexion Pharmaceuticals's overall performance. [35] The drug costs roughly $450,000 a year, and is considered the world's most expensive drug. Alexion Pharmaceuticals Inc has risen higher in 14 of those 24 years over the subsequent 52 week period, corresponding to a historical accuracy of 58.33 % © American Consumer News, LLC dba MarketBeat® 2010-2021. Alexion Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Alexion Pharmaceuticals… Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Moors & Cabot Inc.’s holdings in Alexion Pharmaceuticals were worth $502,000 at the […] Q1 2020. The Investor Relations website contains information about Alexion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Alexion Pharmaceuticals Inc Stock Forecast. David Brennan, a current board member, became interim CEO. [26][27] In September the company announced it was to acquire Syntimmune for $1.2 billion - expanding its rare disease offering. The P/E ratio of Alexion Pharmaceuticals is 35.42, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 32.68. Their forecasts range from $73.00 to $196.00. [46][47], Pharma, the Belgian pharmaceutical industry's association, opened an internal investigation into the affair, for possible breach of the association's ethical standards by Alexion. Acquisition related costs fell significantly from $22 million to just $5 million. View insider buying and selling activity for Alexion Pharmaceuticals or or view top insider-buying stocks. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. [17][18], In December 2020, AstraZeneca announced it would be buying the company; at announcement the deal was worth $39 billion. It employs around 2,400 people worldwide. A number of other large investors have also recently added to or reduced their stakes in ALXN. More than half of people with aHUS end up dying of it as a result of damage to vital organs/organ failure (usually involving the kidneys) caused by uncontrolled complement activation. Do Not Sell My Information. [23], In May 2015, Alexion announced plans to purchase the Lexington firm Synageva BioPharma, a maker of rare disease treatments, in an $8.4 billion stock-and-cash deal. Please log in to your account or sign up in order to add this asset to your watchlist. [6] In 2010, there was an outbreak of hemolytic-uremic syndrome caused by Enterohaemorrhagic Escherichia coli (EHEC) in Germany. Get the latest Alexion Pharmaceuticals (ALXN) stock price quote with real-time news, financials, charts and other important investing information. As of February 12th, there was short interest totaling 7,900,000 shares, an increase of 80.4% from the January 28th total of 4,380,000 shares. Alexion Pharmaceuticals. [51], In 2013, 36% Alexion's sales originated in the US, down from 37% the previous year; 33% came from Europe, down from 35%; Japan accounted for just over 10%. [36], In September 2011, the FDA officially approved the use of Soliris as a treatment for atypical hemolytic-uremic syndrome in both adults and children. [9], When Soliris was first approved, peak annual sales were estimated at $150 million. Alexion Pharmaceuticals, Inc.(NASDAQ:ALXN): Having overcome business challenges presented by the COVID-19 pandemic, the stock of Alexion Pharmaceuticals (ALXN) has been hitting new highs. Specifically, they have bought $0.00 in company stock and sold $3,795,208.00 in company stock. Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology, AstraZeneca Sold Its Stake in Rival Covid-19 Vaccine Maker Moderna for More Than $1 Billion, AstraZeneca sold its stake in Moderna for more than $1 billion last year. DOW 32,485.59. It employs around 2,400 people worldwide. Alexion Pharmaceuticals does not currently pay a dividend. However, ALXN is currently down in pre-market trading. Alexion moved back to New Haven following the completion of New Haven's Downtown Crossing project in December 2015. Alexion Pharmaceuticals Inc. stock rises Friday, still underperforms market. Additionally, big pharmaceutical companies have tended to ignore these markets, creating a niche with minimal competition for Alexion. Community Sentiment. Stock analysis for Alexion Pharmaceuticals Inc (ALXN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. [14], In December 2016, Alexion's board of directors announced new leadership. Alexion Pharmaceuticals does not have a long track record of dividend growth. [4][5] The company is also involved in immune system research related to autoimmune diseases. ", Exec. As a result, Alexion hires public relations firms to help families institute campaigns to pressure their governments to pay for the drug. Alexion Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. (Add your “outperform” vote. Currently, 3.6% of the shares of the stock are sold short. ALXN stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Magnetar Financial LLC, Janus Henderson Group PLC, The Manufacturers Life Insurance Company , Westchester Capital Management LLC, Alpine Associates Management Inc., Carlson Capital L P, and Water Island Capital LLC. View Alexion Pharmaceuticals' Short Interest. 43 employees have rated Alexion Pharmaceuticals CEO Ludwig Hantson on Glassdoor.com. Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini and Tanisha Carino. See what's happening in the market right now with MarketBeat's real-time news feed. Get short term trading ideas from the MarketBeat Idea Engine. ... Rule Breakers High-growth stocks. It is used to treat hypophosphatasia, a rare metabolic disorder. We think it may be wise to bet on the stock now because this company has been receiving multiple regulatory approvals for its products. The biopharmaceutical company earns $2.40 billion in net income (profit) each year or $9.74 on an earnings per share basis. MarketBeat just released five new trading ideas, but Alexion Pharmaceuticals wasn't one of them. Learn about financial terms, types of investments, trading strategies and more. Export data to Excel for your own analysis. [31] In May 2020, the hedge fund Elliott Management Corporation, which acquired a position in Alexion in 2017, had - again - pushed for Alexion to sell itself, months after the drugmaker had rejected the hedge fund's earlier demand. The prices charged have a very high margin above the cost price. Alexion Pharmaceuticals Inc. [ALXN]: Deeper insight into the fundamentals. 02:53PM : 53% of executives say their companies plan to increase M&A in 2021: PwC . Alexion Pharmaceuticals (ALXN) stock price, charts, trades & the US's most popular discussion forums. At the time Proliferon's annual revenue was about $2.5 million and its assets were valued at $2.1 million. [42] It was also reported that the parents had believed their benefactor was a Dutch organization for patients, and that the PR agency acted with permission from Alexion. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. 102%. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. In Canada, access to the drug is mostly through private clinics; groups such as the Canadian Association of PNH Patients are lobbying to change that. Alexion CEO, Leonard Bell, cited Proliferon's ability to produce an "unlimited amount of antibodies" as the reason for the acquisition. High institutional ownership can be a signal of strong market trust in this company. [16], In September 2017, Alexion announced that it would be closing its Smithfield, RI manufacturing facility. One share of ALXN stock can currently be purchased for approximately $151.59. Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN.". (Add your “underperform” vote.) Q4 2020. Upon completion of merger, Alexion shareholders will own 15% of combined company.[19][20]. Alexion Pharmaceuticals has a P/B Ratio of 2.98. Alexion Pharmaceuticals has received 61.88% “outperform” votes from our community. Alexion Pharmaceuticals (NASDAQ:ALXN) will be posting its quarterly earnings results before the market opens on Thursday, February 4th. [47], In October 2017 the FDA approved the use of Soliris to treat adult patients with generalized myasthenia gravis (gMG). View the real-time ALXN price chart on Robinhood and decide if you want to buy or sell commission-free.
Sofie Z Hohenbergu, Bupa Health Insurance Review, Giba Net Worth, Webcam Adlerhof Straubenhardt, Handball Meisterschaft Frauen,
Neue Kommentare